This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors CI
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump MT
Transcript : Cybin Inc. - Special Call
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder CI
Cybin Inc. announced that it expects to receive $150 million in funding CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting CI
Transcript : Cybin Inc. - Special Call
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses CI
HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating MT
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Transcript : Cybin Inc. - Special Call
Chart Cybin Inc.
More charts
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.4762 CAD
Average target price
6.089 CAD
Spread / Average Target
+1,178.75%
Consensus
  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. News Cybin Inc.
  5. Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW